Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | EVP, Chief Commercial Officer | August 05, 2026 | August 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jazz Pharmaceuticals plc
Report date August 05, 2026 · Filed August 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 47,131 |
Reported balance
After 2026-08-05 transaction · row 1
1 source rowRow 1 · 2026-08-05 · Tax withholding · Disposed 780 · Balance 47,131 F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 05, 2026 Filed Aug 7, 2026 22:01 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 780 | $261.62 | $204,063.60 |
DisclosureSEC source: 0001805688-26-000014 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,131 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 22:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,527 | $237.72 | $600,718.44 |
DisclosureSEC source: 0001805688-26-000012 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,911 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 29, 2026. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 6,907 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001805688-26-000008 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 6,907 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vested in 36 equal monthly installments thereafter. The option was fully vested as of March 2, 2024. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 6,907 | $235.41 | $1,625,976.87 |
DisclosureSEC source: 0001805688-26-000008 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,272 Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 6,907 | $109.45 | $755,971.15 |
DisclosureSEC source: 0001805688-26-000008 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 05, 2026 Filed Mar 9, 2026 21:23 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,503 | $188.69 | $472,291.07 |
DisclosureSEC source: 0001805688-26-000006 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,272 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 22:19 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 9,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-26-000004 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,775 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2026, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,599 | $171.16 | $273,684.84 |
DisclosureSEC source: 0001805688-26-000002 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,993 F3 · kind: Shares withheld from the vesting and distribution of performance share awards to satisfy the reporting person's tax obligations. Read SEC document |
| January 16, 2026 Filed Jan 22, 2026 01:17 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,637 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-26-000002 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,592 F1 · kind: Represents ordinary shares of the Issuer delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 140 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025. Read SEC document |
| August 05, 2025 Filed Aug 7, 2025 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 577 | $116.10 | $66,989.70 |
DisclosureSEC source: 0001765581-25-000051 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,815 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on May 30, 2025. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 00:00 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Disposition to issuerOrdinary Shares | 1,905 | $138.95 | $264,699.75 |
DisclosureSEC source: 0001765581-25-000029 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,226 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000016 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,131 F2 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in full on June 30, 2026. Read SEC document |
| February 27, 2025 Filed Mar 4, 2025 00:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 11,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-25-000016 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,353 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2025, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,365 | $122.62 | $167,376.30 |
DisclosureSEC source: 0001805688-25-000003 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,412 F3 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 23:40 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,533 | $0.00 | $0.00 |
DisclosureSEC source: 0001805688-25-000003 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,777 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2022. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2025, which represents the date on which the level of performance attained was certified. F2 · balance_after: The Reporting Person acquired 166 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 29, 2024. Read SEC document |
| August 02, 2024 Filed Aug 6, 2024 20:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 6,996 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000072 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,078 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of August 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. F2 · balance_after: Includes 160 ordinary shares acquired on May 31, 2024 under a Section 423 Employee Stock Purchase Plan. Read SEC document |
| March 05, 2024 Filed Mar 8, 2024 02:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,474 | $117.53 | $290,769.22 |
DisclosureSEC source: 0001765581-24-000035 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,922 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 00:52 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 5,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-24-000022 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,396 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2024, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 1,038 | $119.13 | $123,656.94 |
DisclosureSEC source: 0001784606-24-000012 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,331 F2 · kind: Shares to be withheld from the vesting and distribution of performance award shares to satisfy the reporting person's tax obligations. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 23:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 2,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001784606-24-000012 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,369 F1 · kind: Represents ordinary shares of Jazz Pharamceuticals that will be delivered pursuant to the terms of performance share awards made to the reporting person on May 5, 2021. The performance-based vesting requirements applicable to such awards were satisfied on January 17, 2024, which represents the date on which the level of performance attained was certified. Read SEC document |
| March 05, 2023 Filed Mar 8, 2023 01:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 2,020 | $142.78 | $288,415.60 |
DisclosureSEC source: 0001765581-23-000019 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,159 F2 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 01:54 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 3,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001765581-23-000019 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,179 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2023, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-23-000008 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,907 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $157.26 | $83,505.06 |
DisclosureSEC source: 0001765581-23-000008 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-23-000008 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-23-000004 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,438 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $159.59 | $84,742.29 |
DisclosureSEC source: 0001765581-23-000004 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 23:43 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-23-000004 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000140 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,969 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $155.45 | $82,543.95 |
DisclosureSEC source: 0001765581-22-000140 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 13, 2022 Filed Dec 15, 2022 23:29 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-22-000140 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · derivative · entry 6 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 532 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · derivative · entry 5 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,031 Underlying: Ordinary Shares · 532 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $155.00 | $82,305.00 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 4 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 532 | $155.00 | $82,460.00 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 Read SEC document |
| November 10, 2022 Filed Nov 14, 2022 23:16 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 532 | $109.45 | $58,227.40 |
DisclosureSEC source: 0001765581-22-000120 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 21:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000109 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,563 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 21:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $156.98 | $83,356.38 |
DisclosureSEC source: 0001765581-22-000109 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 21:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-22-000109 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 531 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000075 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,094 Underlying: Ordinary Shares · 531 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 531 | $155.00 | $82,305.00 |
DisclosureSEC source: 0001765581-22-000075 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 04, 2022 Filed Aug 8, 2022 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 531 | $109.45 | $58,117.95 |
DisclosureSEC source: 0001765581-22-000075 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 22:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 532 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000071 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,625 Underlying: Ordinary Shares · 532 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 22:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 532 | $155.00 | $82,460.00 |
DisclosureSEC source: 0001765581-22-000071 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 12, 2022 Filed Jul 14, 2022 22:15 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 532 | $109.45 | $58,227.40 |
DisclosureSEC source: 0001765581-22-000071 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 8,508 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000065 · edgardoc.xml · derivative · entry 3 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,157 Underlying: Ordinary Shares · 8,508 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, 1/4th vested on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter. Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 8,508 | $155.00 | $1,318,740.00 |
DisclosureSEC source: 0001765581-22-000065 · edgardoc.xml · nonDerivative · entry 2 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,309 Read SEC document |
| June 27, 2022 Filed Jun 29, 2022 21:55 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionOrdinary Shares | 8,508 | $109.45 | $931,200.60 |
DisclosureSEC source: 0001765581-22-000065 · edgardoc.xml · nonDerivative · entry 1 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 21:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,835 | $0.00 Strike: $109.45 | $0.00 |
DisclosureSEC source: 0001765581-22-000063 · edgardoc.xml · derivative · entry 4 Pearce Samantha · CIK 0001805688 · SVP, Head of Europe & Internat 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,665 Underlying: Ordinary Shares · 5,835 shares Expires 2030-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the vesting commencement date of March 2, 2020, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.